Presented by: Dan Some, Ph.D., Wyatt Technology
Presented Live: September 6, 2017
Glycoproteins (GPs) are primary targets of neutralizing and therapeutic antibodies for a large variety of indications including epilepsy and many types of viruses. Many non-IgG therapeutic proteins are themselves GPs. Hence, the characterization of GPs and potential degradants, as well as their interactions with therapeutic or target proteins, is essential for understanding GP targets and developing effective therapeutics. This webinar presents two first-principles techniques for carrying out these analyses in solution: SEC-MALS-UV-RI and CG-MALS.
Unlike common unmodified proteins that are globular in conformation and highly hydrophilic in surface chemistry, GPs cannot be characterized accurately by standard analytical size-exclusion chromatography (SEC). Coupling SEC to multi-angle light scattering (MALS) and differential refractive index (dRI) detection results in a powerful SEC-MALS-UV-RI triple-detection system that can determine the molar mass of the protein and total glycan mass in order to characterize degradants and complexes. Composition-gradient multi-angle light scattering (CG-MALS) utilizes the same detectors with a stop-flow system to quantify the absolute stoichiometry and binding affinity of reversible association between GPs and antibodies or solubilized target proteins.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.